Clinical trial
ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
NCT00016991 · Duke University, Other · Completed
Key facts
| NCT number | NCT00016991 |
|---|---|
| Title | ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse |
| Official title | A Phase II Study of ZD 1839 (NSC 715055) for Patients With First Relapse Glioblastoma Multiforme |
| Lead sponsor | Duke University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | gefitinib |
| Start date | Jun 1, 2001 |
| Completion | Apr 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: